"I believe that the Brazilian pharmaceutical market has changed and improved a lot concerning regulatory demands. Nowadays
it is much clearer, and we can follow all regulations," says Laurena Magnoni, formerly acclaimed for her work with Levemir
at Novo Nordisk, who now heads Besins' Brazilian operations. Besins, a French family-owned company specializing in hormonal
therapies and food supplements, and one of the newest entrants to Brazil, will have to get up to speed on ANVISA quickly.
Hopefully, with an award-winning manager with a long history in the local market, their learning curve will be very steep.
"I am very enthusiastic about the situation of Besins in Brazil. We have a great opportunity, a great market, and we can certainly
reach what the company expects us to," says Magnoni, who looks forward to the first planned launch in Brazil, of Androgel,
a patient-friendly natural testosterone gel developed under a novel technology, which sets it apart from the available alternatives
of orals and injectables. This differentiation will be key to establishing Besins, according to Magnoni: "We have a long-term
strategy to be within the top 100 pharmaceutical companies in Brazil, and we believe that with the products Besins has, it
Laurena de Lameida Magnon, regional director, Besins